Resource utility
Little is known about the molecular pathophysiology in VHL syndrome (van Leeuwaarde et al., 2018) . The iPSC lines presented herein offer a useful resource to study molecular mechanisms behind tumor progression and for drug development to improve treatment of patients with VHL syndrome.
Resource details
Von Hippel-Lindau (VHL) syndrome is characterized by various malignant and benign neoplasms mainly derived from the neural crest lineage (e.g. hemangioblastomas of the brain and spinal cord; renal cysts and clear cell renal carcinoma; pheochromocytoma, pancreatic cysts and neuroendocrine tumors; endolymphatic sac tumors) (van Leeuwaarde et al., 2018) . The syndrome is caused by mutations in the tumor suppressor gene VHL and approximately 80% of cases are familial. The VHL protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF) that regulates gene expression by oxygen (Kaelin Jr., 2005) . Detailed investigations of molecular mechanisms underlying disease pathophysiology and cancer progression in VHL, with the aim to develop novel drugs, have been hampered by lack of accessible human disease models. . We generated human iPSC lines from primary fibroblasts of each patient (VHL2-10, VHL3-9 and VHL4-10) using the Sendai virus reprogramming system (Tables 1-3 ). The three hiPSC lines VHL2-10, VHL3-9 and VHL4-10 were expanded as monolayers in tight colonies and showed typical iPSC morphology with large nucleus-to-cytoplasm ratio, prominent nuclei and defined luminescent borders as seen by Bright-field microscopy ( Fig. 1A ; size bar: 50 μm).
Endogenous expression of the pluripotency markers Nanog, Sox2, TRA-1-60 and SSEA4 was demonstrated at protein level by immunocytochemistry and flow cytometry in the three hiPSC lines, respectively ( Fig. 1C and B; size bar: 100 μm). Cell authentication using a set of 16 polymorphic short tandem repeats (STRs) confirmed that the established iPSC lines matched the donor fibroblasts (data available upon request). Additionally, the three VHL syndrome patient derived hiPSC lines VHL2-10, VHL3-9 and VHL4-10 were confirmed free of Sendai reprogramming vector by RT/PCR (Fig. 1D) .
Analysis of the three hiPSC lines using scorecards confirmed an expression pattern of pluripotency markers corresponding to an undifferentiated state using a reference set of 23 pluripotent stem cell lines ( Fig. 1E) (Fergus et al., 2016) . In order to assess the differentiation potential of the three hiPSC, an embryoid body (EB) differentiation assay was performed. The expression of specific markers for ectoderm, mesoderm and endoderm was carried out by scorecard analysis. The analysis confirmed that the hiPSC lines are capable of differentiating into the three germ layers (Fig. 1E) .
Each of the hiPSC lines VHL2-10, VHL3-9 and VHL4-10 retained the pathogenic VHL gene variant (c.194C > G, c.194C > T and 
SeV-F and SeV-R (RT/PCR) Sendai virus genome GGATCACTAGGTGATATCGAGC/ACCAGACAAGAGTTTAAGAGATATGTATC GAPDH-F and GAPDH-R (RT/PCR)
Glyceraldehyde-3-phosphate dehydrogenase (pos control) TCCACCCATGGCAAATTCCA/AAATGAGCCCCAGCCTTCTC nt440delTCT, respectively) of the donor as confirmed by Sanger sequencing (Fig. 1F) . Genomic integrity was investigated by CytoScan™HD DNA array and no acquired chromosomal aberration was detected in any of the three iPSC lines (Supplementary File 1) (Mills et al., 2011; Wong et al., 2007) . All three iPSC lines tested free of Mycoplasma infection using MycoAlert™ Mycoplasma detection kit. The three different VHL syndrome patient derived iPSC lines generated here will offer a useful resource to study disease pathology, cancer progression and for drug development.
Materials and methods

Culture conditions
Fibroblasts were cultured in DMEM, Sigma cat no: D5796, 10% fetal bovine serum, ThermoFisher Scientific, cat no: 10500056, 2 mM GlutaMAX™, ThermoFisher Scientific, cat no: 35050038, 1% penicillin/ streptomycin, ThermoFisher Scientific, cat no: 15140122 in a humidified atmosphere with 5% CO 2 at 37°C and passaged using TrypLE™ Express, ThermoFisher Scientific, cat no: 12604039, and Defined Trypsin Inhibitor, ThermoFisher Scientific, cat no: R007100. hiPS cells were cultured in Essential-8™ medium, ThermoFisher Scientific, cat no: A1517001, on Vitronectin-XF™, Stem Cell Technologies, cat no: 07180, coated plates (5%CO 2 , 37°C) and passaged with Gentle Cell Dissociation Reagent, Stem Cell Technologies, cat no: 07174. hiPSC lines were subsequently adapted to culture on human Laminin-521, Biolamina, Cat no: LN-521, and passaged using TrypLE™ Expressand Defined Trypsin Inhibitor.
For embryonic body formation hiPSC were dissociated with accutase, Sigma cat no: A6964, seeded into an AggreWell™400 plate, Stem Cell Technologies, cat no: 34421, in AggreWell™ medium, Stem Cell Technologies, cat no: 05893, supplemented with 10 μM Rho-kinase inhibitor Y27632, Stem Cell Technologies, cat no: 72304 according to protocol. Formed embryoid bodies were transferred to non-adherent culture plates and further differentiated for four weeks.
Reprogramming
Fibroblasts were reprogrammed using CytoTune™-iPS 2.0 Sendai Reprogramming Kit, ThermoFisher Scientific, cat no: A16517, expressing the four Yamanaka factors hKlf4, hc-Myc, hSox2, hOct3/4. hiPSC colonies were manually picked for passage 1 to Vitronectin™-XL coated dishes and clonally expanded (see Culture conditions). Established hiPSC lines were adapted to culture on LN-521 (see Culture Conditions) past passage P10.
Cell authentication
Cell authentication on DNA from fibroblasts and hiPSC lines was performed at Eurofins Genomics, Germany using AmpFLSTR™ Identifiler™ PCR Amplification Kit, ThermoFisher Scientific, cat no: 4322288.
Genome stability
Genome stability was analysed on DNA from the three hiPSC lines at Uppsala University Hospital, Clinical Genetics unit, Uppsala, using the CytoScan™HD Array, ThermoFisher Scientific, cat no: 901835.
RT-PCR
RNA was isolated using miRNeasy micro kit, Qiagen, cat no: 217084. cDNA was synthesized using High Capacity cDNA Synthesis kit, ThermoFisher Scientific, cat no: 4368814 from 1 μg of total RNA. Detection of Sendai virus was performed by PCR on a "MyCycler" thermal cycler, BIORAD, by a total of 35 cycles (95°C -30 s, 55°C -1 min, 72°C -1 min) with 1/10 of the cDNA reaction with primers SeV-F and SeV-R. GAPDH was used as positive control. Samples were run without template as negative control.
PCR products (expected sizes SeV: 195 bp (SeV), GAPDH: 325 bp) were visualized by 1% agarose gel electrophoresis. Ladder: GeneRuler 100 bp DNA ladder, ThermoFisher Scientific, cat no: SM0243.
Immunofluorescence
Cells were fixed in 4% formaldehyde for 5 min and pre-incubated in 1xPBS, 1%BSA, 0,3% TritonX100. Primary antibodies (mouse anti-NANOG, rabbit anti-SOX2) were diluted in preincubation buffer and incubated at 4°C overnight. Secondary antibodies (donkey anti-mouse AF647, donkey anti-goat AF488) were incubated at room temperature for 60 min. Nuclear marker, DAPI (1 μg/ml), Sigma cat no: D8417 was incubated for 10 min at room temperature and specimens were mounted onto microscope slides using CFM-3 mounting medium, Citifluor. Specimens were imaged using an AxioImager (Zeiss).
Flow cytometry
iPSCs were harvested with accutase, Sigma cat no: A6964 and washed in 1%BSA/1xPBS. Primary antibodies (mouse-IgG anti-SSEA4, mouse-IgM anti TRA-1-60) were incubated at room temperature for 30 min. Secondary antibodies (goat anti-mouse IgM AF488, goat antimouse IgG AF555) were incubated for 20 min at room temperature. Cells were analysed on a LSR-FORTESSA (BD).
Scorecard assay
RNA was extracted (see RT-PCR) and quality was assessed by Agilent BioAnalyzer. Samples were run on TaqMan® hPSC Scorecard™ Panel, ThermoFisher Scientific, cat no: A15872/A15870 following manufacturer's protocol (Fergus et al., 2016) . Scorecards were analysed with company's software at https://apps.thermofisher.com/ hPSCscorecard/home.htm.
Mycoplasma
Presence of mycoplasma in hiPSC lines was assessed on cell culture supernatants using MycoAlert™ Mycoplasma Detection kit, Lonza, cat no: LT07-318.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.scr.2019.101474.
